According to a new research, an injectable drug used for diabetics, Liraglutide, might help obese people lose weight, even those who do not currently have diabetes. In a study conducted earlier, it was found that not only did the drug help control patients' blood sugar levels, it also promoted weight loss.

Taking the earlier cue further, the new research confirmed the results and said that the drug could possibly be administered to people who are not diabetic. Further studies and researches are, however, needed to prove the safety of using the drug without any signs of diabetes and its exact effectiveness.

Liraglutide, which is currently under FDA review, was approved in Europe earlier this year, and is marketed as Victoza. Despite frequent bouts of vomiting and nausea as the drug's side-effects, patients did not seem to have any problems injecting it, as noted by the research's authors.

However, more studies are still required before Liraglutide can be promoted as a weight loss drug as well. "Whether long-term use of an injectable drug is palatable as a treatment for obesity is yet to be established", said Dr. George A. Bray of Louisiana State University's Pennington Biomedical Research Center.

While the FDA, and many other critics, have their doubts, the finds are definitely interesting. Denmark based maker of Liraglutide or Victozam Novo Nordisk funded the study.